Durvalumab, also known as MEDI 4736, is an monoclonal IgG1 antibody targeting PD-L1 (Programmed death-ligand 1). It blocks the binding of PD-L1 to PD-1. The binding of Programmed Cell Death Protein 1 (PD-1), also known as CD279, a receptor expressed on activated T cells, to its ligands PD-L1 and PD-L2, negatively...

Description: Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer...